Figure 8. . Glutamate–cystine antiporter activity assayed by extracellular D4-cystine uptake and determined by relative steady state levels of intracellular D2-cysteine in cisplatin-resistant and wild-type ovarian cancer cell lines OVCAR-5 and SKOV-3.

Cisplatin-resistant ovarian cancer cells exhibit significantly greater uptake of extracellular D4-cystine compared with their wild-type counterparts. Data representative of at least n = 3 individual experiments.

*p< 0.05.